Cargando…

Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations

IPX203 is an investigational oral extended-release capsule formulation of carbidopa and levodopa. The pharmacodynamics and efficacy of IPX203 were compared with immediate-release carbidopa-levodopa (IR CD-LD) in this open-label, rater-blinded, multicenter, crossover study in patients with advanced P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modi, Nishit B., Mittur, Aravind, Dinh, Phillip, Rubens, Robert, Gupta, Suneel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791502/ https://www.ncbi.nlm.nih.gov/pubmed/31306216 http://dx.doi.org/10.1097/WNF.0000000000000354

Ejemplares similares

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
por: Morgan, John C., et al.
Publicado: (2018)

Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials
por: Nausieda, Paul A., et al.
Publicado: (2015)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2016)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
por: Waters, Cheryl H., et al.
Publicado: (2015)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Single‐ and Multiple‐Dose Pharmacokinetics and Pharmacodynamics of PN‐943, a Gastrointestinal‐Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers
por: Modi, Nishit B., et al.
Publicado: (2021)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Kwak, Nayoung, et al.
Publicado: (2022)

Editorial comments: treatment of motor fluctuations in Parkinson’s disease
por: Korczyn, Amos D.
Publicado: (2011)

Nausea as a non-motor fluctuation in Parkinson’s disease
por: Weisbach, Emily, et al.
Publicado: (2022)

Gender differences in non-motor fluctuations in Parkinson’s disease
por: Donzuso, Giulia, et al.
Publicado: (2023)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease
por: Wang, Luxi, et al.
Publicado: (2017)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
por: Kakimoto, Asako, et al.
Publicado: (2023)

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease
por: Höglund, Arja, et al.
Publicado: (2020)

Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease
por: Kleiner-Fisman, Galit, et al.
Publicado: (2011)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks
por: Ramesh, Vishwajith, et al.
Publicado: (2022)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
por: Sako, Wataru, et al.
Publicado: (2023)

Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease
por: Virmani, Tuhin, et al.
Publicado: (2016)

Rapid motor fluctuations reveal short-timescale neurophysiological biomarkers of Parkinson’s disease
por: Ahn, Minkyu, et al.
Publicado: (2020)

Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease
por: Löhle, Matthias, et al.
Publicado: (2022)

mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson’s disease
por: Erb, M. Kelley, et al.
Publicado: (2020)

Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson’s Disease: An Exploratory Study
por: Carpi, Matteo, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials
por: Ruan, Xinglin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k7upmg5ul6ll400q1b2o3a7n5t